Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dieter Petzinna"'
Publikováno v:
Clinical Drug Investigation. 25:589-595
Objective:The aim of the study was to investigate the efficacy and tolerability of long-term acarbose therapy in type 2 diabetic patients. Study design: In this double-blind, single-centre group comparison, patients were randomised to receive either
Autor:
Byron J. Hoogwerf, Dieter Neuser, Ronald B. Goldberg, Dieter Petzinna, Alice Benson, Andreas Brückner
Publikováno v:
Clinical Drug Investigation. 25:579-587
Objective: To assess the safety profile of acarbose treatment over a 1-year period at a dose range of 50–300mg three times daily in patients with type 1 or type 2 diabetes mellitus. Study design and patients: In this 56-week, double-blind, parallel
Publikováno v:
European Journal of Cardiovascular Prevention & Rehabilitation. 11:412-415
The moderate increase in postprandial plasma glucose in subjects with impaired glucose tolerance has been shown to be a predictor of cardiovascular disease. In the randomised STOP-NIDDM trial, we could demonstrate that lowering postprandial plasma gl
Publikováno v:
Clinical Drug Investigation. 23:679-686
Multiple oral therapies are required long term for the majority of patients with type 2 diabetes mellitus to achieve acceptable glycaemic levels; alternatively, insulin therapy has to be initiated. This study investigated the addition of acarbose to
Autor:
Erwin Bischoff, Jörg Dr. Pfitzner, Rolf Angerbauer, Gunter Thomas, Delf Schmidt, Hilmar Bischoff, Joachim Bender, Agostino Faggiotto, Dieter Petzinna, Michael C Porter
Publikováno v:
Atherosclerosis. 135:119-130
The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited
Publikováno v:
European heart journal. 26(20)
To investigate pulse pressure (PP) as an independent predictor of coronary heart disease (CHD) risk.On the basis of a 10-year follow-up of 5389 men aged 35-65 at recruitment into PROCAM, we used a proportional hazards model to calculate the effect of